Dec 8, 2015

PaxVax, Inc. Announces $105 Million Investment from Cerberus Capital Management

Cerberus Investment Represents a Majority Economic Interest in the Company; Company Benefits from Increased Capital Base, Facilitating Focus on Long-term Growth REDWOOD CITY, Calif. and NEW YORK, Dec. 8, 2015 /PRNewswire/ -- PaxVax, Inc. ("PaxVax"), a Redwood City, California-based specialty...


May 11, 2015

PaxVax Appoints Nima Farzan Chief Executive Officer

REDWOOD CITY, Calif. -- May 11, 2015 -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that the Board of Directors has appointed Nima Farzan Chief Executive Officer and President. In this role, he will...


Apr 22, 2015

PaxVax Announces Global Expansion of Commercial Network for its Typhoid Vaccine Vivotif

REDWOOD CITY, California – April, 22 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements for its commercial typhoid vaccine Vivotif®. These agreements will ensure...


Jan 21, 2015

Specialty Vaccine Company PaxVax Appoints Nima Farzan as President

REDWOOD CITY, Calif. – January 21, 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Nima Farzan as President and Chief Operating Officer (COO). Mr. Farzan, who has served as PaxVax...


Dec 8, 2014

PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

REDWOOD CITY, Calif. – December 8, 2014 – PaxVax Inc., a specialty vaccine company focused on travel and biodefense, today announced positive results from a Phase 3 safety and lot-to-lot consistency trial of its single-dose oral cholera vaccine candidate, PXVX0200,...


Sep 3, 2014

Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer

REDWOOD CITY, CALIF. – September 3, 2014 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will...


Aug 7, 2014

Specialty Vaccine Company PaxVax Expands Global Commercial Team

REDWOOD CITY, CALIF. – August 7, 2014 -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the expansion of its global commercial team with the appointments of Jonathan Klock as Vice President of Sales and...


Jul 28, 2014

Specialty Vaccine Company PaxVax Secures Up to $60 Million in Financing

REDWOOD CITY, Calif. – July 28, 2014 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has closed up to $50 million in secured debt financing from an investment fund managed by Pharmakon...


Jul 28, 2014

PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif

REDWOOD CITY, Calif. -- July 28, 2014 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility...


Jul 1, 2014

Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study

New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World REDWOOD CITY, Calif. – July 1, 2014 – PaxVax Inc., a specialty vaccine company...


Jun 10, 2014

PaxVax Signs R&D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections

Redwood City and San Diego, Calif., -- June 10, 2014 -- PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it...


May 27, 2014

Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference

REDWOOD CITY, Calif. – May 27, 2014 – PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer...


May 1, 2014

Specialty Vaccine Company PaxVax Selected to Present at Cavendish Global Health Impact Forum

Redwood City, May 1, 2014 -- PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer Ken Kelley will present...


Apr 29, 2014

Specialty Vaccine Company PaxVax Appoints Jim Connolly to Board of Directors

Industry Veteran Joins Company as it Readies for the Anticipated Commercial Launch of its Cholera Vaccine for Travelers Redwood City – APRIL 29, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social...


Mar 25, 2014

PaxVax to Present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

Presentation and Webcast Held Friday, March 28 at 9:30 a.m. Eastern Time MENLO PARK and SAN DIEGO – MARCH 25, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure...


2 of 3123